METHOTREXATE TREATMENT FOR SARCOIDOSIS-INDUCED HYPERCALCEMIA
AACE Clinical Case Reports
|November 27, 2020
Summary
Methotrexate (MTX) effectively treats hypercalcemia caused by sarcoidosis. This case study shows MTX can manage calcium levels when prednisone is insufficient, demonstrating its therapeutic potential.
Area of Science:
- Pulmonology
- Endocrinology
- Rheumatology
Background:
- Sarcoidosis is an inflammatory disease that can cause hypercalcemia.
- Hypercalcemia in sarcoidosis is often managed with corticosteroids, but relapses can occur.
- Alternative treatments are needed for persistent or recurrent hypercalcemia in sarcoidosis.
Observation:
- A 65-year-old woman with sarcoidosis presented with hypercalcemia (11.4 mg/dL).
- Initial treatment with prednisone normalized calcium levels but hypercalcemia recurred upon dose reduction.
- The patient had bilateral hilar lymphadenopathy and pulmonary nodules consistent with sarcoidosis.
Findings:
- Methotrexate (MTX) was initiated at 15 mg/week, allowing for a reduction in prednisone dosage to 3 mg daily.
- This regimen successfully controlled hypercalcemia.
- Discontinuation of MTX led to a rapid increase in calcium levels to 17 mg/dL, confirming MTX efficacy.
Implications:
- Methotrexate is a viable treatment option for managing sarcoidosis-induced hypercalcemia.
- MTX may allow for reduced corticosteroid use in patients with sarcoidosis and hypercalcemia.
- This case highlights the importance of exploring steroid-sparing agents for sarcoidosis complications.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
337
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
337
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
304
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
304
01:29Therapeutic Drug Monitoring: Affecting Factors
94
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
94
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
266
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
266